Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Burixafor HBr, the hydrobromide salt of Burixafor (TG-0054), is a novel, potent and orally bioavailable antagonist of CXCR4 (CXC chemokine receptor 4) with potential anti-inflammatory activity. It is an anti-angiogenic medication that dissolves in water well and may be useful in the treatment of choroid neovascularization. Burixafor, also called TG-0054, is an orally bioavailable inhibitor that binds to the CXC chemokine receptor 4 (CXCR4) and has the ability to mobilize hematopoietic stem cells. In order to stop stromal derived factor-1 (SDF-1 or CXCL12) from binding to the CXCR4 receptor and subsequent receptor activation, burixafor binds to the chemokine receptor CXCR4. This may prevent the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood.
Targets |
CXCR4
|
---|---|
References |
Molecular Formula |
C27H60BR3N8O6P
|
---|---|
Molecular Weight |
647.631345748901
|
Exact Mass |
646.31
|
Elemental Analysis |
C, 37.56; H, 7.00; Br, 27.76; N, 12.98; O, 11.12; P, 3.59
|
CAS # |
1191450-19-7
|
Related CAS # |
1191450-19-7 (HBr); 1191448-17-5 (free acid)
|
Appearance |
White to off-white solid powder
|
SMILES |
C1CCC(CC1)NCCCNCC2CCC(CC2)CNC3=NC(=CC(=N3)N4CCN(CC4)CCP(=O)(O)O)N.Br
|
InChi Key |
ZXUVXYNBMUFEMK-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C27H51N8O3P.BrH/c28-25-19-26(35-15-13-34(14-16-35)17-18-39(36,37)38)33-27(32-25)31-21-23-9-7-22(8-10-23)20-29-11-4-12-30-24-5-2-1-3-6-24;/h19,22-24,29-30H,1-18,20-21H2,(H2,36,37,38)(H3,28,31,32,33);1H
|
Chemical Name |
2-[4-[6-amino-2-[[4-[[3-(cyclohexylamino)propylamino]methyl]cyclohexyl]methylamino]pyrimidin-4-yl]piperazin-1-yl]ethylphosphonic acid;hydrobromide
|
Synonyms |
TG-0054; Burixafor; TG0054; Burixafor HBr; TG 0054; Burixafor HBr hydrate; Burixafor trihydrobromide trihydrate
|
HS Tariff Code |
2934.99.03.00
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O: ~50 mg/mL (~65.0 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 20 mg/mL (26.01 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.5441 mL | 7.7205 mL | 15.4409 mL | |
5 mM | 0.3088 mL | 1.5441 mL | 3.0882 mL | |
10 mM | 0.1544 mL | 0.7720 mL | 1.5441 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02478125 | Terminated | Drug: Burixafor Hydrobromide Drug: Docetaxel |
Prostate Cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
July 2016 | Phase 1 |